SOUTHWEST ONCOLOGY GROUP

西南肿瘤集团

• 批准号: 3558186
• 负责人: David A Lipschitz
• 金额: $ 9.98万
• 依托单位: UNIV OF ARKANSAS FOR MED SCIS
• 依托单位国家: 美国
• 财政年份: 1984
• 资助国家: 美国
• 起止时间: 1984-07-15 至 1992-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3558186
• 关键词: alpha benzopyrone; antineoplastics; breast neoplasms; carcinoembryonal antigen; cimetidine; combination cancer therapy; cooperative study; esophagus neoplasm; fluorouracil; head /neck neoplasm; human old age (65+); human subject; human therapy evaluation; kidney neoplasms; laser therapy; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer radiation therapy; patient /disease registry; platinum

The primary purpose of this proposal is for the University of Arkansas for Medical Sciences to participate actively in cooperative clinical trials of the Southwest Oncology Group. The Southwest Oncology Group is a major multidisease, therapeutic research organization consisting of 30 full member institutions. The University of Arkansas for Medical Sciences has been a member of the Southwest Oncology Group for 30 years. A full complement of 22 physician investigators in a variety of scientific disciplines at the University of Arkansas for Medical Sciences is committed to participation in cancer chemotherapy, surgery, and radiotherapy clinical trials. The University of Arkansas for Medical Sciences has assumed a leadership role in the Group in the study of optimal management of elderly cancer patients. Dr. David Lipschitz is Chairman of the Standing Committee on Cancer Management in the Elderly for the Southwest Oncology Group. A large number of new cases of head and neck cancer seen at the University of Arkansas for Medical Sciences will be entered onto Southwest Oncology Group protocols or local pilot studies. Likewise, many new cases of melanoma referred to the surgical oncologists will be entered onto cooperative clinical trials. In addition, the University of Arkansas for Medical Sciences has 11 physicians who are active participants in the Southwest Oncology Group Cooperative Group Outreach Program protocols. An average of 52 patients a year have been registered on Cooperative Group Outreach Program protocols. With the establishment of the Arkansas Cancer Research Center at the University of Arkansas for Medical Sciences the referral of new cancer patients will be increased. Furthermore, the close association of investigations in multidisciplinary oncology clinics at the Cancer Center, will ensure high quality participation of the University of Arkansas for Medical Sciences in multimodal group protocols.

该提议的主要目的是针对大学 阿肯色州的医学科学积极参与 西南肿瘤学组的合作临床试验。 这 西南肿瘤学小组是一种主要的多疾病治疗 研究组织由30个正式机构组成。 阿肯色大学医学科学大学一直是 西南肿瘤学集团成员已有30年。 全面补充了22位医师调查员 阿肯色大学的科学学科 科学致力于参与癌症化疗， 手术和放疗临床试验。 大学 阿肯色州医学科学在 该小组在最佳的老年癌症研究中 患者。 David Lipschitz博士是主席 老年人癌症管理委员会 西南肿瘤学小组。 大量的新案例 和阿肯色大学医学上的颈部癌 科学将进入西南肿瘤学组协议 或当地的试点研究。 同样，许多新的黑色素瘤病例 转介到外科肿瘤学家将被输入 合作临床试验。 此外，阿肯色大学 因为医学科学有11位活跃参与者的医生 在西南肿瘤学集团合作集团外展 程序协议。 平均每年有52名患者 在合作小组外展计划方案中注册。 随着阿肯色州癌症研究中心的建立 在阿肯色大学医学科学大学的转诊 新的癌症患者将增加。 此外，近距离 多学科肿瘤诊所的调查协会 在癌症中心，将确保 阿肯色大学多式联运小组的医学科学 协议。